Show All
Whom should I contact regarding investor inquiries?

Please email or call 833-561-1310.

How can I receive Sotera Health’s press releases, financial reports and other information?

Please visit this page to sign up for email alerts related to Sotera Health.

Where is Sotera Health's corporate headquarters?
9100 South Hills Blvd, Suite 300, Broadview Heights, Ohio 44147
What is Sotera Health’s fiscal year-end?
December 31
On which exchange is Sotera Health listed and what is the ticker symbol?
Sotera Health’s stock is traded on the NASDAQ Global Select Market under the symbol “SHC”.
When did Sotera Health go public?
Sotera Health’s first day of trading on the NASDAQ Global Select Market was November 20, 2020.
Does Sotera Health pay dividends?
We do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all earnings in the foreseeable future will be used for operations, growth of our business and the repayment of indebtedness.
Who is Sotera Health's transfer agent and how do I contact them?

Computershare is our stock transfer agent. For questions regarding your shares, certificates, and other share-specific information, please contact Computershare in one of several way

By Mail, regular delivery:
P.O. Box 505005
Louisville, KY 40233-5005

By phone:
Toll Free: 1-800-736-3001
Toll Number : +1-781-575-3100
For contact information and FAQs:

By Overnight Delivery:
462 South 4th Street
Louisville, KY 40202

How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?
Contact our transfer agent Computershare:
Does Sotera Health have a direct stock purchase plan?
Sotera Health does not currently offer a direct stock purchase plan.
Who is Sotera Health's auditor?
Ernst & Young LLP.
How do I communicate with the Board?

Shareholders and other interested parties can communicate with our Board of Directors by email at: The Corporate Secretary reviews all communications sent to the Board. Inquiries that relate to the functions of the Board or a Board Committee will be relayed to the Board, Board Committee, or to individual directors, as appropriate. The Secretary will not relay to the Board or its members inquiries unrelated to the duties and responsibilities of the Board or its Committees, including solicitations, advertisements, job applications or resumes, service or product inquiries, complaints, or any materials that are threatening or illegal.

What products are sterilized by Sterigenics?
  • Sterigenics operates 48 facilities in 13 countries to ensure medical devices, pharmaceutical products, and food are safe for people to use and consume.
  • Sterigenics sterilizes and decontaminates products that protect over one million patients and consumers every day.
  • This includes surgical instruments, catheters and procedure kits, IV administration sets, personal protective equipment (PPE) such as drapes/gowns, wound protection sleeves, tubing sets and many more.
  • Without these essential devices, vital procedures would not occur and patients’ lives would be at risk.
Why is EO sterilization necessary?
  • As explained by the FDA, for many medical devices, sterilization with EO is the only method that effectively sterilizes and does not damage the device during the sterilization process.
  • Approximately 50% of sterile medical products in the U.S. are sterilized using EO.
  • Without EO sterilization, infection risk associated with surgical procedures and other forms of care could be meaningfully increased.
Why can’t Sterigenics use other forms of sterilization instead of EO?
  • Sterigenics provides sterilization services using Gamma, EO, E-beam and X-ray technologies.
  • Sterigenics does not determine which sterilization method to use. The method of sterilization is determined by FDA sterility requirements and the medical product manufacturer based on the materials and the design of the product being sterilized.
  • In late 2019, the FDA stated, “there are no readily available processes or facilities that can serve as viable alternatives to those that use ethylene oxide to sterilize these devices. In short: this method is critical to our health care system and to the continued availability of safe, effective and high-quality medical devices.”
Should I be concerned that I am exposed to EO?
  • EO is in the air around us.
  • EO is a common building block in many of the products we use in our daily lives, including household cleaners, personal care products and pharmaceuticals. It is also emitted by ordinary cooking activities, from car and truck engines and natural gas combustion, and is produced naturally by plants and the human body.
Does Sterigenics consistently comply with all relevant rules and regulations?
  • Yes. Sterigenics’ facilities have been industry leading, consistently outperforming environmental regulatory standards for decades.
Regulatory Oversight
Lack of evidence exists for low-level EO environmental exposure causing personal injury.
  • No generally accepted science demonstrates that low-level EO exposure from Sterigenics' facilities cause medical conditions.
  • EO is a naturally occurring substance, unlike many other chemicals at issue in other environmental litigation.
  • EO consistently occurs in the environment from natural/everyday human activity, often at levels above those to which the general public is exposed to long-term from the Sterigenics facilities.
  • The EPA and others now acknowledge background levels of EO, contrary to the view the EPA took for some time after it published the IRIS EO assessment.
Independent research does not support a connection between EO sterilization and cancer.
  • A recent meta-analysis of studies regarding cancer risks among workers exposed to EO concluded that the most recent and informative studies on the topic “do not support the conclusion that exposure to EO is associated with an increased risk of lymphohematopoietic cancers (LHC) or breast cancer.”
  • Another study reevaluated historical exposures to EO among sterilization workers in the National Institute of Occupational Safety and Health (NIOSH) study cohort that was relied upon by the EPA in its 2016 IRIS risk assessment. The review found that the trend in EO exposures during the study period was opposite to the trend indicated in the NIOSH study “suggesting that the US EPA’s exclusive reliance on the NIOSH cohort to estimate EO cancer risk should be re-examined.”
Sterigenics operates safely and in compliance with environmental regulatory requirements.
  • Sterigenics consistently complies with environmental permits issued specifically for each of its sterilization facilities.
  • Sterigenics disclosed its EO emissions for decades in federal and state filings, even when others in the industry did not.
  • Sterigenics has implemented leading safety practices and continues to work with regulators and others to enhance the safety of EO sterilization.
No class actions pending against Sterigenics for personal injury or property damage.
  • Pending claims are individual claims; results in one trial will relate to the individual claimants involved – Sterigenics will defend remaining claims as they go to trial over time.
  • Although some pending claims are consolidated for efficiency in pre-trial proceedings, any trials are expected to address individual plaintiff claims, not claims of large classes of people.
No precedent for liability for low-level EO exposure claims like these.
  • The Plaintiffs’ bar seeks to create a new kind of mass tort relating to this ubiquitous, naturally occurring substance emitted at permitted facilities.
  • There is no precedent for liability for alleged personal injury or property damage related to low-level EO emissions from facilities consistently operating under governmental permits.
While the Company is vigorously defending this litigation and expects to prevail, it faces risks.
  • Plaintiffs are represented by motivated attorneys across multiple jurisdictions, who will disagree with the evidence the Company presents and who will present differing evidence and allegations, including government reports suggesting long-term health risk at EO sterilization facilities.
  • The cases are pending in multiple state court systems with varying procedures and law.
  • Many cases are likely to be resolved in jury trials with associated uncertainty.
  • Investors should review the latest Sotera Health Company Annual Report on Form 10-K and the latest Sotera Health Company Quarterly Report on Form 10-Q including the section titled “Cautionary Note Regarding Forward-Looking Statements” in each, for a detailed discussion of Risk Factors and litigation affecting the Company.
EO sterilization plants are regulated under the National Emission Standards for Hazardous Air Pollutants (NESHAP).

NESHAP are stationary source standards for hazardous air pollutants. The regulation sets standards for allowable emissions levels, as well as a framework for ongoing compliance and inspection (i.e., reviewing records, inspecting facilities, interviewing personnel).

The medical sterilization industry has been anticipating an update to EO regulation under NESHAP for multiple years. A notice of proposed rulemaking is anticipated during 2022, with a final rule to follow completion of the rulemaking process. Sterigenics is making investments today to best position its EO sterilization facilities for compliance with future regulations.

If EO is a longstanding method of medical device sterilization that is essential to the U.S. healthcare system and highly regulated, why is there controversy over its use?

Recent controversy related to EO is ultimately grounded in a study published in December 2016 by EPA’s Integrated Risk Information System program (IRIS). IRIS assessments are a source of information used by EPA, state and local health agencies, other federal agencies, and international health organizations. It is not a safety limit and is not intended to be a regulatory standard.

In 2016, EPA’s IRIS group completed a review and reclassified EO from “Probably Carcinogenic” to “Carcinogenic” and updated its inhalation unit risk estimate. During this multi-year review, EPA’s independent Science Advisory Board (SAB) raised several questions about the basis for these conclusions. The IRIS group’s final report failed to resolve those questions.

The IRIS update gained attention in 2018, when the EPA used it to evaluate nationwide cancer risks as part of its National Air Toxics Assessment (NATA). NATA’s computer-simulated assessment combined the widely disputed IRIS inhalation unit risk estimate with outdated 2014 public emissions data from facilities across the country that are not always reflective of current emission control systems. This flawed analysis implied that 106 census tracts across the country, including the Sterigenics facilities located in Willowbrook, IL, Smyrna, GA, and Santa Teresa, NM, were identified as having an elevated risk of cancer due to EO, including several locations near other medical sterilizers that use EO.

Placing IRIS in perspective.

The IRIS value of 0.1 parts per trillion of EO is an inhalation unit risk estimate, which assumes that inhaling EO 24 hours per day, 7 days per week for 70 years might increase the risk that 1 additional person in 1 million will get cancer.

The IRIS program has been widely questioned in the past by reputable organizations such as the Government Accountability Office and a National Academy of Sciences panel. EO exists naturally at concentrations significantly exceeding the IRIS value, including in the human body.

EO sterilization is widely used to keep medical devices safe.

For many medical devices, EO is the only sterilization method that effectively sterilizes without damaging the device during the sterilization process. Medical devices made from certain polymers (plastic or resin) or that have multiple layers of packaging or hard-to-reach places (for example, catheters) are likely to be sterilized with EO.

The method of sterilization for a particular product or device is determined by the medical product manufacturer based on a variety of considerations, including FDA sterility requirements and internationally agreed consensus standards, the materials used and design of the product being sterilized, and the intended use of the product. Without EO sterilization, infection risk associated with surgical procedures and other forms of care could be meaningfully increased.

For any additional investor questions, please contact / 833-561-1310.